Related Experiment Video
Updated: Aug 6, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines
Christopher D Coldren1, Barbara A Helfrich, Samir E Witta
1Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, C272, Denver, 80262, USA. chris.coldren@uchsc.edu
Abstract:
Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) produce objective responses in a minority of patients with advanced-stage non-small cell lung cancer (NSCLC), and about half of all treated patients progress within 6 weeks of instituting therapy. Because the target of these agents is known, it should be possible to develop biological predictors of response, but EGFR protein levels have not been proven useful as a predictor of TKI response in patients and the mechanism of primary resistance is unclear. We used microarray gene expression profiling to uncover a pattern of gene expression associated with sensitivity to EGFR-TKIs by comparing NSCLC cell lines that were either highly sensitive or highly resistant to gefitinib. This sensitivity-associated expression profile was used to predict gefitinib sensitivity in a panel of NSCLC cell lines with known gene expression profiles but unknown gefitinib sensitivity. Gefitinib sensitivity was then determined for members of this test panel, and the microarray-based sensitivity prediction was correct in eight of nine NSCLC cell lines. Gene and protein expression differences were confirmed with a combination of quantitative reverse transcription-PCR, flow cytometry, and immunohistochemistry. This gene expression pattern related to gefitinib sensitivity was independent from sensitivity associated with EGFR mutations. Several genes associated with sensitivity encode proteins involved in HER pathway signaling or pathways that interrelate to the HER signaling pathway. Some of these genes could be targets of pharmacologic interventions to overcome primary resistance.
Insights
Identifying gene expression patterns can predict non-small cell lung cancer (NSCLC) response to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). This discovery offers potential strategies to overcome primary resistance to these targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show limited efficacy in advanced non-small cell lung cancer (NSCLC).
- Primary resistance and rapid progression are common challenges, with EGFR protein levels being an unreliable predictor of TKI response.
- The mechanisms underlying primary resistance to EGFR-TKIs in NSCLC remain largely unclear.
Purpose of the Study:
- To identify a gene expression profile predictive of sensitivity to EGFR-TKIs in NSCLC.
- To explore potential molecular targets for overcoming primary resistance to EGFR-TKIs.
Main Methods:
- Microarray gene expression profiling was employed to compare gefitinib-sensitive and gefitinib-resistant NSCLC cell lines.
- A predictive model based on the identified gene expression profile was validated in an independent panel of NSCLC cell lines.
- Quantitative reverse transcription-PCR, flow cytometry, and immunohistochemistry were used to confirm gene and protein expression differences.
Main Results:
- A specific gene expression pattern associated with gefitinib sensitivity was identified.
- The microarray-based prediction of gefitinib sensitivity was accurate in 8 out of 9 NSCLC cell lines tested.
- The identified sensitivity-associated gene expression profile was independent of EGFR mutations.
- Several genes within the profile are involved in HER pathway signaling or interconnected pathways.
Conclusions:
- Gene expression profiling can effectively predict EGFR-TKI sensitivity in NSCLC.
- The identified gene expression signature provides insights into mechanisms of primary resistance.
- Specific genes identified may represent novel therapeutic targets for overcoming resistance to EGFR-TKIs in NSCLC.
